The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial
Authors:
- 15 May 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 112 (1) , 55-62
Abstract
Taxane-induced peripheral neuropathy (TIPN) is a dose-limiting adverse effect. Ganglioside-monosialic acid (GM1) functions as a neuroprotective factor. We assessed the effects of GM1 on the prevention of TIPN in breast cancer patients. We conducted a randomized, double-blind, placebo-controlled trial including 206 patients with early-stage breast cancer planning to receive taxane-based adjuvant chemotherapy with a follow-up of more than 1 year. Subjects were randomly assigned to receive GM1 (80 mg, day −1 to day 2) or placebo. The primary endpoint was the Functional Assessment of Cancer Treatment Neurotoxicity subscale score after four cycles of chemotherapy. Secondary endpoints included neurotoxicity evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 and the Eastern Cooperative Oncology Group neuropathy scale. All statistical tests were two-sided. In 183 evaluable patients, the GM1 group reported better mean Functional Assessment of Cancer Treatment Neurotoxicity subscale scores than patients in the placebo group after four cycles of chemotherapy (43.27, 95% confidence interval [CI] = 43.05 to 43.49 vs 34.34, 95% CI = 33.78 to 34.89; mean difference = 8.96, 95% CI = 8.38 to 9.54, P < .001). Grade 1 or higher peripheral neurotoxicity in Common Terminology Criteria for Adverse Events v4.0 scale was statistically significantly lower in the GM1 group (14.3% vs 100.0%, P < .001). Additionally, the GM1 group had a statistically significantly lower incidence of grade 1 or higher neurotoxicity assessed by Eastern Cooperative Oncology Group neuropathy scale sensory neuropathy (26.4% vs 97.8%, P < .001) and motor neuropathy subscales (20.9% vs 81.5%, P < .001). The treatment with GM1 resulted in a reduction in the severity and incidence of TIPN after four cycles of taxane-containing chemotherapy in patients with breast cancer.Keywords
Funding Information
- Qilu Pharmaceutical and Sun Yat-sen University Cancer Center
This publication has 38 references indexed in Scilit:
- Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumorsWorld Journal of Surgical Oncology, 2013
- Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease miceProceedings of the National Academy of Sciences, 2012
- Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1Journal of Clinical Oncology, 2011
- Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapyBreast Cancer Research and Treatment, 2010
- Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast CancerJournal of Clinical Oncology, 2006
- Measuring the side effects of taxane therapy in oncologyCancer, 2003
- Chemotherapy dose reduction and delay in clinical practiceEuropean Journal of Cancer, 2000
- The Role of GM1 and Other Gangliosides in Neuronal Differentiation Overview and New FindingsaAnnals of the New York Academy of Sciences, 1998
- The Impact of Diabetes Mellitus on the Toxicity of Therapy for Advanced Ovarian CancerGynecologic Oncology, 1996
- Biosynthesis and Function of GangliosidesScience, 1976